At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLGL Sol-Gel Technologies
Post-Market Trading 12-24 13:58:16 EST
0.9799
-0.6701
-40.61%
盘后0.9100
-0.0699-7.13%
13:55 EST
High1.10
Low0.8500
Vol3.01M
Open0.9800
D1 Closing1.65
Amplitude15.15%
Mkt Cap27.30M
Tradable Cap8.07M
Total Shares27.86M
T/O2.92M
T/O Rate36.58%
Tradable Shares8.24M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Wall Street Set to Open Mixed Tuesday Ahead of Holiday Break
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.